Search research articles
Contact Us
Filters
Showing results (71-80 of 80) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 80 results.
Clinical Genitourinary Cancer
|
March 31, 2019
Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients
Guillaume Klausner, Idriss Troussier, Julian Biau, et al.
World Journal of Urology
|
August 31, 2013
Nomograms to predict late urinary toxicity after prostate cancer radiotherapy
Romain Mathieu, Juan David Ospina Arango, Véronique Beckendorf, et al.
European Urology Oncology
|
November 8, 2025
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial
Thomas Zilli, Dirk Böhmer, Andreas Roeder, et al.
European Urology Oncology
|
February 8, 2023
The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study
David Pasquier, Thomas Lacornerie, Stéphane Supiot, et al.
Annals of Surgical Oncology
|
October 27, 2018
How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort
Daniel Pietrasz, Olivier Turrini, Véronique Vendrely, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 3, 2004
The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity
Véronique Beckendorf, Stéphane Guérif, Elisabeth Le Prisé, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 15, 2010
70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial
Véronique Beckendorf, Stéphane Guerif, Elisabeth Le Prisé, et al.
Critical Reviews in Oncology/Hematology
|
March 28, 2022
Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group
Ariane Lapierre, Christophe Hennequin, Amandine Beneux, et al.
European Urology
|
August 15, 2025
Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial
Nicolas Demogeot, Paul Sargos, Julia Salleron, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 13, 2016
Influence of Nucleoshuttling of the ATM Protein in the Healthy Tissues Response to Radiation Therapy: Toward a Molecular Classification of Human Radiosensitivity
, Adeline Granzotto, Mohamed Amine Benadjaoud, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 80) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 80 results.
Clinical Genitourinary Cancer
|
March 31, 2019
Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients
Guillaume Klausner, Idriss Troussier, Julian Biau, et al.
World Journal of Urology
|
August 31, 2013
Nomograms to predict late urinary toxicity after prostate cancer radiotherapy
Romain Mathieu, Juan David Ospina Arango, Véronique Beckendorf, et al.
European Urology Oncology
|
November 8, 2025
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial
Thomas Zilli, Dirk Böhmer, Andreas Roeder, et al.
European Urology Oncology
|
February 8, 2023
The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study
David Pasquier, Thomas Lacornerie, Stéphane Supiot, et al.
Annals of Surgical Oncology
|
October 27, 2018
How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort
Daniel Pietrasz, Olivier Turrini, Véronique Vendrely, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 3, 2004
The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity
Véronique Beckendorf, Stéphane Guérif, Elisabeth Le Prisé, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 15, 2010
70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial
Véronique Beckendorf, Stéphane Guerif, Elisabeth Le Prisé, et al.
Critical Reviews in Oncology/Hematology
|
March 28, 2022
Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group
Ariane Lapierre, Christophe Hennequin, Amandine Beneux, et al.
European Urology
|
August 15, 2025
Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial
Nicolas Demogeot, Paul Sargos, Julia Salleron, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 13, 2016
Influence of Nucleoshuttling of the ATM Protein in the Healthy Tissues Response to Radiation Therapy: Toward a Molecular Classification of Human Radiosensitivity
, Adeline Granzotto, Mohamed Amine Benadjaoud, et al.
Page
of 8